LifeStance Health Group, Inc. (LFST)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Bullish pullback_to_support: GTC limit 13.70 at the settled 2026-11-13 regular-session low 13.675 inside a rising stacked-MA uptrend (ADX 40.5, price above SMA20/50/200); structural stop 13.55 is sub-floor so the mandated 1.0×ATR pullback floor sets the stop at 13.04, targets 15.02 / 16.01, R/R 2.00.
Company overview
LifeStance Health Group, Inc. provides outpatient mental healthcare services through a network of subsidiaries. It offers psychiatric evaluations, psychological testing, and various therapeutic modalities for conditions like anxiety, depression, and PTSD. Services are accessible online and in-person across 32 states.
Fundamental
fairLifeStance shows profitability improvements but faces high valuation and control issues.
Improving outpatient mental-health operator: revenue up 24% and GAAP net income of $60.2M through nine months of 2026, $170M of operating cash flow, net debt/EBITDA of 1.6x, no going-concern or covenant issues, and a 20.9% five-year revenue CAGR. Offsetting that are a demanding 74x trailing P/E and 36x EV/EBITDA, an unremediated material weakness in internal control over financial reporting, roughly 29% revenue concentration in two payors, and persistent one-way insider and sponsor selling. Verdict: mixed - a real fundamental turnaround that is already priced for success.
Sentiment
fairMedia sentiment is positive, but insider selling and a large secondary offering weigh on the outlook.
Dominant driver is the announced 2026-11-05 Q3 2026 print — revenue +25.3% to $455.9M, an EPS beat and a raised FY2026 outlook — which the tape demonstrably rewarded ('stock soars', fresh 52-week high), but a second announced event, the 45,000,000-share selling-stockholder secondary launched and priced 2026-11-09 at $13.12, offsets it as a persistent float overhang. The media delta is determinately positive (baseline polarity_score ≈ +0.04 → scoring ≈ +0.30, both windows well above the three-item threshold) and no severe red flag fired, but two moderate red-flag caps applied — the growth-context secondary supply event and materially conflicting bullish/bearish catalyst signals — holding the setup to the middle of the scale.
Technical
goodThe stock is in a confirmed uptrend, digesting recent highs with a pullback opportunity.
Trend and structure carry this setup: price 14.08 sits above a rising, fully stacked MA complex (sma20 13.41 > sma50 12.79 > sma200 9.67; ema9 14.01, ema21 13.53) with ADX14 at 40.52 and still climbing, and the 2026-11-09/11-10 offering-volume surge has given way to a three-session 13.675–14.54 flag on shrinking volume — constructive post-secondary digestion. Momentum is positive but decelerating (RSI 60.15; MACD 0.50/0.44 with a contracting +0.06 histogram) and price is marginally below the 9-day WMA (14.18) and DEMA14/TEMA14, which is why the chart scores 4 rather than 5. The plan buys the pullback: a GTC limit at 13.70 at the settled 2026-11-13 regular-session low 13.675; the structural stop 13.55 is sub-floor (0.23 ATR), so the mandated 1.0×ATR pullback floor widens it to 13.04, giving 2.00 R/R to the +2 ATR target 15.02. Invalidation is a break of 13.04, through the 2026-11-09 low 13.20 and the $13.12 secondary price, which would mean the post-offering base failed.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

